The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen.
The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
FOX 9 Minneapolis-St. Paul on MSN4d
Generic prescription drug prices marked up as high as 5,000%, investigation findsA new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...
Wednesday, 92 independent, mom-pop pharmacies across the state will close their doors for a day of advocacy in Topeka. It’s a ...
Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...
“PBMs are nothing but pharmacy benefit manipulators.” Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs ...
The Federal Trade Commission on Jan. 14 published a second interim staff report on the prescription drug middleman industry, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback